Compare OneSpan Inc (OSPN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? OneSpan Inc trades at $15.2 (market cap $571.66M), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 214× OneSpan Inc's market cap, and OneSpan Inc pays a 3.37% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| OSPN | VRTX | |
|---|---|---|
Market Cap | $571.66M | $122.33B |
Sector | Technology | Health |
52-Week High | $16.32 | $529.59 |
52-Week Low | $10.15 | $366.54 |
Enterprise Value | $529.87M | $117.07B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $15.51, up 0.26% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and a low P/E of 8.57, indicating potential undervaluation. Recent earnings have consistently beaten expectations, and the company announced a $0.13 dividend for H1 2026. Analyst sentiment is positive with a 66.7% buy rating, though the consensus price target of $13.50 is below the current price.
The outlook for OSPN is cautiously optimistic, supported by solid fundamentals and positive earnings momentum. Key opportunities include attractive valuation and consistent profitability. Risks include negative net cash flow trends and competitive pressures in the cybersecurity sector. Investors should weigh the strong analyst buy sentiment against the below-consensus price target.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
